R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 58.41 CNY -2.81% Market Closed
Market Cap: 5.6B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

R&G PharmaStudies Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

R&G PharmaStudies Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
R
R&G PharmaStudies Co Ltd
SZSE:301333
Other Long-Term Assets
ÂĄ8.7m
CAGR 3-Years
33%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Other Long-Term Assets
ÂĄ2.4B
CAGR 3-Years
-15%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Other Long-Term Assets
ÂĄ953.7m
CAGR 3-Years
22%
CAGR 5-Years
28%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Other Long-Term Assets
ÂĄ548.8m
CAGR 3-Years
30%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Other Long-Term Assets
ÂĄ363.9m
CAGR 3-Years
21%
CAGR 5-Years
-24%
CAGR 10-Years
54%
W
WuXi XDC Cayman Inc
HKEX:2268
Other Long-Term Assets
ÂĄ6.4m
CAGR 3-Years
134%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

R&G PharmaStudies Co Ltd
Glance View

Market Cap
5.6B CNY
Industry
Life Sciences Tools & Services

R&G PharmaStudies Co., Ltd. engages in the provision of clinical trial outsourcing services. The company is headquartered in Beijing, Beijing and currently employs 1,926 full-time employees. The company went IPO on 2022-08-02. The firm's main businesses include clinical trial operation services (CO Services), clinical trial site management services (SMO Services), biological sample testing services (BA Services), data management and statistical analysis services (DM/ST Services), clinical trials Consulting Services, Clinical Pharmacology Services (CP Services) and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
57.24 CNY
Overvaluation 2%
Intrinsic Value
Price
R

See Also

What is R&G PharmaStudies Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
8.7m CNY

Based on the financial report for Dec 31, 2023, R&G PharmaStudies Co Ltd's Other Long-Term Assets amounts to 8.7m CNY.

What is R&G PharmaStudies Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
33%

Over the last year, the Other Long-Term Assets growth was -5%. The average annual Other Long-Term Assets growth rates for R&G PharmaStudies Co Ltd have been 33% over the past three years .

Back to Top